Local, national & international business news and events.
The fund will divest from many fossil fuels in the next five years and sell its shares in other companies that contribute to global warming by 2040. — NYT: Top Stories
A federal lawsuit says that Moda Latina BZ, a Los Angeles County company, deceived consumers into thinking they could make up to $500 a week selling perfume, makeup and other items. — NYT: Top Stories
Net Sales increased 7%; Organic Net Sales increased 8% reflecting continued elevated demand for Campbell’s brands. Earnings Before Interest and Taxes (EBIT) increased 45% to $461 million. Adjusted EBIT increased 18% to $463 million. Earnings Per Share (EPS) from Continuing Operations of
Crestron adds Teams software to its new 70 Series hardware to create a workplace solution that gives on-site employees comprehensive, real-time control over their office environment. ROCKLEIGH, N.J.–(BUSINESS WIRE)–Crestron, the global leader in workplace technology, today announces the new Crestron 70 Series
PRINCETON, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)–$BMY #BMS—Bristol Myers Squibb (NYSE: BMY) and Scripps Research today announced that Bristol Myers Squibb has endowed a chair in chemistry at Scripps Research to advance scientific research critical to drug discovery. Scripps Research has named
Ms. Jones, currently a senior vice president at the network, will become the highest-ranking Black woman in the TV news industry. — NYT: Top Stories
It’s made of Italy’s second-most widely planted red grape, and the wines are priced to go. How come they don’t get more respect? — NYT: Top Stories
Agreement is fundamental element of Bayer’s new Cell & Gene Therapy strategy Bayer to enter CAR T-cell therapy space and expand oncology development pipeline with groundbreaking technology Recognizes the leading position of Atara’s technology platform in allogeneic cell therapy Collaboration will focus
Combined Phase 1b/2 CARTITUDE-1 study presented at ASH 2020 Annual Meeting show 97 percent overall response rate and 12-month progression free survival rate of 77 percent at median follow up of 12.4 months SOMERSET, N.J.–(BUSINESS WIRE)–Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”),